躁うつ病におけるプラズマオピオイド活性

Evaluation of the 'Jumping to conclusions' bias in different subgroups of the at-risk mental state: from cognitive basic symptoms to UHR criteria.

Psychological medicine·2016

[Comparison of Two Symptom-Triggered Treatments for Alcohol Withdrawal: HAES vs. SAB-P].

Fortschritte der Neurologie-Psychiatrie·2016

What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?

European psychiatry : the journal of the Association of European Psychiatrists·2014

Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics.

International journal of psychiatry in clinical practice·2014

Principles of practice from the European expert panel on the contemporary treatment of schizophrenia.

International journal of psychiatry in clinical practice·2014

The importance of treatment acceptability to patients.

International journal of psychiatry in clinical practice·2014

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Interrogating roles for VTA dopamine neurons in locomotion and ultrasonic vocalizations elicited by different classes of rewarding drugs.

Psychopharmacology·2026

Transcriptional Response to Chronic Long-Access Fentanyl Self-Administration in Rat Habenula and Amygdala.

Addiction biology·2026

Shank3b deficiency drives anxiety-like behaviors via impaired GABAergic inhibition and enhanced intrinsic excitability in the basolateral amygdala.

Neuropharmacology·2026

Evaluation of Bronchial Receptors with Concentration-Response Curves, Bitterness Assessment, and Computer Simulations.

Cell biochemistry and biophysics·2026

Lead (Pb) and the NMDA Receptor Hypofunction Hypothesis: A Comparative Review of Non-Essential Metal Exposures in Schizophrenia.

Current environmental health reports·2026

Open-label placebo effects on psychological distress and hair cortisol in a randomized controlled trial - the moderating role of the five-factor personality traits.

Comprehensive psychoneuroendocrinology·2026

関連する実験動画

躁うつ病におけるプラズマオピオイド活性

関連する概念動画

Evaluation of the 'Jumping to conclusions' bias in different subgroups of the at-risk mental state: from cognitive basic symptoms to UHR criteria.

[Comparison of Two Symptom-Triggered Treatments for Alcohol Withdrawal: HAES vs. SAB-P].

What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?

Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics.

Principles of practice from the European expert panel on the contemporary treatment of schizophrenia.

The importance of treatment acceptability to patients.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Interrogating roles for VTA dopamine neurons in locomotion and ultrasonic vocalizations elicited by different classes of rewarding drugs.

Transcriptional Response to Chronic Long-Access Fentanyl Self-Administration in Rat Habenula and Amygdala.

Shank3b deficiency drives anxiety-like behaviors via impaired GABAergic inhibition and enhanced intrinsic excitability in the basolateral amygdala.

Evaluation of Bronchial Receptors with Concentration-Response Curves, Bitterness Assessment, and Computer Simulations.

Lead (Pb) and the NMDA Receptor Hypofunction Hypothesis: A Comparative Review of Non-Essential Metal Exposures in Schizophrenia.

Open-label placebo effects on psychological distress and hair cortisol in a randomized controlled trial - the moderating role of the five-factor personality traits.

関連する実験動画

躁うつ病におけるプラズマオピオイド活性

関連する概念動画

関連記事